Effect of a second primary thyroid carcinoma on patients with head and neck squamous cell carcinoma

Tolisano, Anthony M.; Klem, Christopher; Lustik, Michael B.; Sniezek, Joseph C.; Golden, J. Blake

doi:10.1002/hed.24121

Cited by 4 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While increased rates of incidental detection with more sensitive imaging tools and more frequent use of ultrasound could explain some of the incidence increase, we would also expect more sensitive imaging to detect other solid tumours, which we did not observe. Multiple studies have found positive associations between radiation therapy, but not chemotherapy (Meadows et al , ), and the risk for subsequent thyroid cancer after a diagnosis of head and neck cancer, AML, or HL (Ron et al , ; Meadows et al , ; Tolisano et al , ), and some studies have described thyroid disorders associated with rituximab use (Raterman et al , ; Hartmann, ). Our findings suggest that the increased risk of thyroid cancer post‐rituximab occurred in DLBCL patients with either localized/regional or advanced stage disease regardless of radiation therapy use.…”

Section: Discussionmentioning

confidence: 99%

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Clarke

Rosenberg

et al. 2017

Br J Haematol

View full text Add to dashboard Cite

Summary With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for SPMs among 23,879 patients who survived at least 1 year after a first primary DLBCL diagnosed during 1989–2012, compared to the general population in California. Cumulative incidence (CMI) of SPMs, accounting for the competing risk of death, also was calculated. We found that the incidence of acute myeloid leukaemia (AML) nearly doubled in the post-rituximab era [SIR (95%CI) 4.39 (2.51–7.13) pre- (1989–2000) and 8.70 (6.62–11.22) post-rituximab (2001–2012)]. Subsequent thyroid cancer was rare pre-rituximab, but increased substantially after 2001 [0.66 (0.08–2.37) vs. 2.27(1.44–3.41)]. The 5-year CMI for all SPMs (4.77% pre- vs. 5.41% post-rituximab, P=0.047), AML (0.15% vs. 0.41%, P=0.003), thyroid cancer (0.03% vs. 0.15%, P=0.003) and melanoma (0.25% vs. 0.42%, P=0.020) were greater in DLBCL patients diagnosed in the post-versus pre-rituximab period. This study provides insight into the changing pattern of SPM occurrence after the introduction of rituximab, which may elucidate the aetiology of SPMs and should guide future cancer surveillance efforts among DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Clarke

Rosenberg

et al. 2017

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…Great advances have been made in recent years on standard treatments, including surgical procedures, chemotherapeutic agents, and radiation technology. Although most patients achieve complete remission (CR), relatively higher recurrence and second primary tumor incidence rates after curative therapy compared with other solid tumors might be one of the plausible reasons for the persistently poor 5‐year survival rate in recent decades . Unfortunately, reliable tools to monitor disease response or progression in patients with HNSCC are still lacking.…”

Section: Introductionmentioning

confidence: 99%

The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer

Wang

Chang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Background This study aimed to evaluate the role of baseline circulating tumor cells (CTCs) before and during concurrent chemoradiotherapy and attempted to determine the impacts of CTCs on the outcomes in patients with head and neck squamous cell carcinoma. Methods CTCs were detected using a negative selection strategy and flow cytometry protocol. Results We observed a significant correlation between baseline CTCs and staging (P = 0.001). The CTC counts were significantly reduced within 2‐4 weeks in 47 concurrent chemoradiotherapy responders (P < 0.001). Change of CTC counts correlates with progression‐free survival (PFS, P = 0.01) and overall survival (OS, P = 0.01). CTC decline status was an independent prognostic factor in PFS (P = 0.03) and OS (P = 0.05) in multivariate analyses. Conclusion In chemoradiotherapy responders, CTCs are significantly reduced. CTC decline within the first month indicates a longer PFS and OS, suggesting that the dynamics of CTCs could be more important than CTC number alone.

show abstract

“…It has been noted that head and neck carcinoma is often associated with second primary cancers, though these are usually other cancers in the head and neck, lung or oesophagus which have developed due to common risk factors including smoking and alcohol use [5]. Incidental papillary thyroid carcinoma as a finding in specimens from surgical management of head and neck carcinoma is also common, [6,8] and is associated with a poorer prognosis overall [9]. However, prognosis and treatment in these cases is ultimately guided by the head and neck cancer staging, [10] as it is the more aggressive of the two cancers.…”

Section: Discussionmentioning

confidence: 99%

Synchronous carcinoma of the thyroid and hypopharynx; a diagnostic and management challenge

McMurran

Rasul

et al. 2020

MedNEXTJ Med Health Sci

View full text Add to dashboard Cite

A 73-year-old Chinese origin woman presented with a right neck swelling associated with recent swallowing issues and hoarseness. She had an apparent goitre and a right posterior neck swelling. An ultrasound guided fine needle aspiration demonstrated papillary thyroid carcinoma in both thyroid lobes and right neck lymphadenopathy. While awaiting total thyroidectomy and neck dissection she presented with haemoptysis. She was found to have an exophytic mass in right pyriform fossa. The CT scan confirmed an intralaryngeal extension of the thyroid mass via thyroid cartilage and metastatic disease in the lung. Unexpectedly histology showed that the tissue from the right pyriform fossa was squamous cell carcinoma and papillary carcinoma in the thyroid was confirmed. She had synchronous cancers in the thyroid and hypopharynx. Synchronous tumours are a big challenge to diagnose and to treat. In her case the CT scan was misleading. We discuss this unusual presentation of synchronous head and neck cancers and difficulty in managing them.

show abstract

Effect of a second primary thyroid carcinoma on patients with head and neck squamous cell carcinoma

Abstract: The development of SPTC in patients with HNSCC results in decreased overall length of survival. © 2015 Wiley Periodicals, Inc. Head Neck 38: E890-E894, 2016.

Cited by 4 publications

References 13 publications

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer

Synchronous carcinoma of the thyroid and hypopharynx; a diagnostic and management challenge

Contact Info

Product

Resources

About